News blog
IS Pharma
- BY: Andrew Hore |
- POSTED: 27/07/2010 |
Specialist pharma products supplier IS Pharma says that trading is in line with expectations in the first three months of this financial year.
Sales of Variquel, a treatment for uncontrolled bleeding from oesophageal varices, continue to grow. The first launch of oral pain treatment Episil was in the UK earlier in July. It will be launched in other European countries in the next 18 months.
The company has also recognised the remaining £700,000 of payments for the sale of Volplex and Isoplex
At 62.5p a share, up 2.75p, IS Pharma is valued at £19.2m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|